The effects of folate supplementation on some coagulation parameters and oxidative status surrogates.
OBJECTIVE
To determine whether folate treatment, besides decreasing homocysteine (tHcy), improves coagulation status, oxidative stress and endothelial dysfunction and whether these depend on genetic polymorphism of the enzyme methylenetetrahydrofolate reductase (MTHFR).


METHODS
Fifty-seven volunteers (males 30, females 27, mean age 61.2 years) with high coronary risk or manifest atherosclerotic disease and tHcy concentration of at least 20 micro mol/l participated in an open, prospective study - 1 month of placebo period, followed by 2 months of treatment with folate 10 mg daily. Concentrations of tHcy were measured using high-pressure liquid chromatography with fluorescence detection. Other variables were measured using commercial kits, and polymorphism of MTHFR was detected using a polymerase chain reaction.


RESULTS
Folate treatment resulted in a significant decrease of tHcy and fibrinogen, while plasminogen and antithrombin III significantly increased. Glutathione peroxidase, glutathione and superoxide dismutase significantly increased after the folate treatment; moreover, malonyldialdehyde and von Willebrand factor decreased concomitantly. The individual MTHFR polymorphism did not influence the outcomes of folate treatment.


CONCLUSIONS
Folate treatment resulted not only in tHcy decrease, but also in an improvement of hypercoagulation, oxidative stress and endothelial dysfunction. The sufficiently high dose of folate seems to be able to decrease plasma tHcy in all three individual MTHFR polymorphism groups, to almost the same post-treatment concentrations.
Mayer
Otto
O
Centre of Preventive Medicine, 2nd Department of Internal Medicine, Charles University Hospital, 13 E. Benese St., 305 99 Pilsen, Czech Republic. mayerjr@lfp.cuni.cz
Simon
Jaroslav
J
Rosolová
Hana
H
Hromádka
Milan
M
Subrt
Ivan
I
Vobrubová
Ivana
I
D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005492:Folic Acid / Q000097:blood / Q000627:therapeutic use*; D006397:Hematinics / Q000097:blood / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000097:blood / Q000235:genetics; D011110:Polymorphism, Genetic; D011446:Prospective Studies
D006397:Hematinics; D006710:Homocysteine; D005492:Folic Acid; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2)